Ginseng Extract Helps Soothe Liver Damage From Fatty Liver Disease

Jim Crocker
24th January, 2024

Ginseng Extract Helps Soothe Liver Damage From Fatty Liver Disease

Ginseng (Panax ginseng)

Photo adapted from: Nina Filippova / CC BY (Source)
Nonalcoholic steatohepatitis (NASH) is a severe form of nonalcoholic fatty liver disease (NAFLD), a growing global health concern[2]. NAFLD encompasses a range of liver conditions from simple fat accumulation to inflammation and liver damage. NASH, specifically, is characterized by inflammation and fibrosis – scarring – of the liver, potentially leading to cirrhosis and liver failure. Currently, effective treatments for NASH are limited, creating an urgent need for new therapeutic strategies. Researchers at Kangwon National University have investigated a potential new approach to treating NASH, focusing on a specific inflammatory pathway and a natural compound that may disrupt it[1]. Their work centers around the NLRP3 inflammasome, a complex within cells that plays a key role in triggering inflammation. Inflammation is a critical component of NASH progression, and understanding how to control it is vital for developing effective treatments. Inflammation in liver disease, including NASH, is a complex process involving multiple pathways[3]. A key feature of inflammasome activation is that it requires two signals to initiate inflammation, acting as a safeguard against overreaction. However, when activated, inflammasomes like NLRP3 can amplify inflammation by releasing signaling molecules like IL-1β, which then further stimulates the immune system[3]. This creates a cycle of increasing inflammation and liver damage. Studies have shown that the NLRP3 inflammasome is particularly important in the development of NASH and related conditions like alcohol-associated liver disease[4]. The study began with an investigation into Panax ginseng, a plant used in traditional medicine, known for its potential anti-inflammatory properties. Researchers separated the chemical components of P. ginseng into polar and non-polar groups, testing each to see if they could affect the NLRP3 inflammasome. They found that the non-polar fractions, extracted using ethyl acetate, were effective at reducing the release of IL-1β and blocking the activation of caspase-1 – an enzyme crucial for inflammasome function. Further analysis pinpointed a specific compound within these fractions, called panaxydol (PND), as the key inflammasome inhibitor. PND was shown to block several steps in the NLRP3 inflammasome activation process: it reduced the release of inflammatory signals, prevented pyroptosis (a type of inflammatory cell death), and stopped the formation of the inflammasome complex itself. Importantly, the researchers demonstrated that PND specifically targeted the NLRP3 pathway, rather than affecting other inflammatory processes. They believe PND interacts with a specific part of the NLRP3 protein – the ATP binding motif – to disrupt its function. To confirm these findings, the researchers tested PND in a mouse model of NASH, where mice were fed a diet designed to induce the disease. The results showed that PND reduced inflammation in the liver tissue and improved the overall development of NASH. This suggests that PND has the potential to be developed into a therapeutic agent for the condition. This research builds on existing knowledge of the role of inflammation in NASH[5]. It identifies a specific natural compound, PND, that can target a key inflammatory pathway, the NLRP3 inflammasome, offering a potential new avenue for treatment. While further research is needed to confirm these findings and assess the safety and efficacy of PND in humans, this study provides a promising step towards developing new therapies for NASH.

MedicineHealthBiotech

References

Main Study

1) Panaxydol extracted from Panax ginseng inhibits NLRP3 inflammasome activation to ameliorate NASH-induced liver injury.

Published 22nd January, 2024

https://doi.org/10.1016/j.intimp.2024.111565

Related Studies

2) Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention.

https://doi.org/10.1038/nrgastro.2017.109

3) Inflammasome activation and function in liver disease.

https://doi.org/10.1038/nrgastro.2015.94

4) Role of the Inflammasome in Liver Disease.

https://doi.org/10.1146/annurev-pathmechdis-032521-102529

5) Pathogenesis of Nonalcoholic Steatohepatitis: An Overview.

https://doi.org/10.1002/hep4.1479


Related Articles

An unhandled error has occurred. Reload 🗙